Drug intelligence / Profile preview

SA030

Development stage: Phase 1
Lead developer: Suzhou Siran Biotech
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

SA030 is a small interfering RNA (siRNA) therapeutic developed by Suzhou Siran Biotechnology for the treatment of obesity. It specifically targets activin receptor-like kinase 7 (ALK7), a type I receptor for the TGF-beta superfamily that plays a role in regulating energy homeostasis and adipose tissue function. The drug utilizes GalNAc (N-acetylgalactosamine) conjugation technology to facilitate targeted delivery. SA030 is currently being evaluated in a Phase 1, randomized, double-blind, placebo-controlled study to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy overweight or obese adults.

Targets

ACVR1C (Activin A Receptor Type 1C)

Beyond the preview

Go deeper on SA030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA030.

Explore the full profile